Shareholding disclosure

ADDEX PHARMACEUTICALS LTD

Declared position

4.82%

Threshold

Crossed downwards

Timeline

Published

21.07.2010

Transaction

—

Voting rights breakdown

Voting rights acquired2.22%

Voting rights sold4.82%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAA7K00063

Beneficial owner

ADDEX PHARMACEUTICALS LTD

Declared address

ADDEX PHARMACEUTICALS LTD, 1228 PLAN-LES-OUATES

Déclaration de position d'aliénation rétroactive.

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

ADDEX PHARMACEUTICALS LTD

Addex Therapeutics Ltd21.07.2010TAA7K00063

Disclosure summary

ADDEX PHARMACEUTICALS LTD disclosed a holding in Addex Therapeutics Ltd on the disposal side, published by SIX Exchange Regulation on 21.07.2010, at 4.82% of voting rights. Notice category: Single shareholder.

Disclosed position

4.82%

Voting rights sold

Voting rights acquired2.22%

Voting rights sold4.82%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

ADDEX PHARMACEUTICALS LTD disclosed a holding in Addex Therapeutics Ltd, published on 21.07.2010.

Publication date21.07.2010

Issuing companyAddex Therapeutics Ltd

Beneficial ownerADDEX PHARMACEUTICALS LTD

Declared addressADDEX PHARMACEUTICALS LTD, 1228 PLAN-LES-OUATES

CategorySingle shareholder

Voting rights acquired2.22%

Voting rights sold4.82%

Below threshold0%

ExchangeXSWX

Notification IDTAA7K00063

Conditions

Déclaration de position d'aliénation rétroactive.

Source: SIX Exchange Regulation · Publication date: 21.07.2010

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open